A Study of RO5310074 in Patients With Psoriatic Arthritis
| Status: | Archived |
|---|---|
| Conditions: | Arthritis, Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Rheumatology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2011 |
| End Date: | March 2012 |
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
This randomized, double-blind. placebo-controlled study will assess the safety,
tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in
patients with psoriatic arthritis who have an inadequate response to oral disease-modifying
antirheumatic drugs (DMARDs) or non-steroidal anti-rheumatic drugs (NSAIDs). Patients will
be randomized in cohorts to receive either 6 intravenous doses of RO5310074 or placebo.
Anticipated time on study treatment is 12 weeks.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials